Articles related to SARCOMA

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.

Ipsen voluntarily withdrew tazemetostat in follicular lymphoma and epithelioid sarcoma after 18 of 318 SYMPHONY-1 participants developed hematologic second primary malignancies, including three deaths.

“Emerging data from this confirmatory study have highlighted a safety profile that is unfavorable compared to that previously observed in clinical evaluation.” — Christelle Huguet, PhD, Ipsen

The belief that only painful masses are worrisome is incorrect – tumor growth rate and size remain the most crucial indicators for potential malignancy.

Dedifferentiated liposarcoma, a malignancy with significant metastatic potential, requires precise diagnosis through MRI, PET scans, and genetic testing. MDM2 and CDK4 are pivotal markers for distinguishing DDL from other sarcomas.

The recent uncovering of KSHV’s method of commandeering cell metabolism for cancer progression not only highlights a novel therapeutic target but also emphasizes the need for vigilant monitoring in immunocompromised patients, where such viral activations are more likely to precipitate aggressive cancers.